NovoCure (NVCR) Set to Announce Quarterly Earnings on Thursday

NovoCure (NASDAQ:NVCR) is projected to issue its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to announce earnings of ($0.2349) per share and revenue of $182.28 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

NovoCure (NASDAQ:NVCR) last released its earnings results on Thursday, July 23rd. The medical equipment provider reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.20. NovoCure had a negative net margin of 21.25% and a negative return on equity of 44.00%. The firm had revenue of $183.58 million for the quarter, compared to analysts’ expectations of $172.44 million. During the same quarter last year, the company earned ($0.36) EPS. NovoCure’s quarterly revenue was up 15.6% on a year-over-year basis. On average, analysts expect NovoCure to post ($1.21) EPS for the current fiscal year and ($0.70) EPS for the next fiscal year.

NovoCure Price Performance

NVCR stock opened at $15.59 on Thursday. NovoCure has a 52 week low of $9.82 and a 52 week high of $21.45. The firm’s 50-day moving average is $16.27 and its two-hundred day moving average is $15.86. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.70 and a current ratio of 2.89.

Wall Street Analyst Weigh In

NVCR has been the subject of several recent analyst reports. Wall Street Zen cut shares of NovoCure from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Wedbush raised their price objective on shares of NovoCure from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. HC Wainwright set a $32.00 target price on NovoCure in a report on Friday, July 24th. Weiss Ratings restated a “sell (d-)” rating on shares of NovoCure in a research report on Thursday, August 27th. Finally, Zacks Research upgraded NovoCure from a “strong sell” rating to a “hold” rating in a research report on Friday, July 24th. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $21.20.

About NovoCure

NovoCure Ltd. (NASDAQ: NVCR) is an oncology company that develops and commercializes therapies based on Tumor Treating Fields (TTFields), low-intensity electric fields designed to disrupt the division of cancer cells. Its treatments are delivered through portable, wearable devices used alongside other cancer therapies.

The company’s principal products include Optune Gio for certain adults with glioblastoma and Optune Lua for adults with unresectable, locally advanced or metastatic pleural mesothelioma and certain forms of metastatic non-small cell lung cancer.